Sales of Johnson’s Baby Powder Halted in US, Canada
Johnson & Johnson says talc-based powder is safe and will still be sold in other countries.
Ovarian Cancer
Lynparza Plus Bevacizumab Approved for First-Line Maintenance in HRD-Positive Advanced Ovarian Cancer
The FDA has approved Lynparza® for use in combination with bevacizumab as first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer
Zejula Approved for Maintenance Treatment of Advanced Ovarian Cancer
Results showed a statistically significant improvement in PFS for Zejula compared with placebo, regardless of biomarker status.
ASCO Guideline: Germline Testing Recommended for All Women Diagnosed With Epithelial Ovarian Cancer
A pervading theme of this guideline was the importance of including genetic counselors in the interpretation and communication of germline and somatic testing results.
Zejula Approved for Late-line Treatment of Recurrent Ovarian Cancer
Zejula, a poly(ADP-ribose) polymerase (PARP) inhibitor, is also approved for maintenance treatment in adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Most HPV-Linked Cancers Due to Types Targeted by 9vHPV Vaccine
Ninety-two percent of human papillomavirus (HPV)-related cancers are attributable to HPV types targeted by the 9-valent HPV vaccine (9vHPV), according to research published in the August 23 issue of the US Centers for Disease Control and Prevention.
USPSTF Recommends Genetic Counseling for High BRCA Risk
But counseling not recommended for women without personal, family history, ancestry associated with BRCA mutations
Zejula Gets Priority Review for Late Stage Ovarian Cancer Indication
The sNDA is supported by data from the multicenter phase 2 QUADRA trial that evaluated the safety and activity of Zejula in 463 patients.
Ready-to-Infuse Chemotherapy Product Infugem Now Available
Sun Pharma announced the launch of Infugem (gemcitabine in sodium chloride injection) 10mg/mL for intravenous (IV) use in a ready-to-administer (RTA) bag.
Niraparib Extends Time Without Symptoms in Ovarian Cancer
Findings based on phase 3 study of maintenance therapy with PARP inhibitor following treatment
